© 2015

Drug Treatment of Sleep Disorders

  • Antonio Guglietta

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages i-viii
  2. General Concepts

    1. Front Matter
      Pages 1-1
    2. Chiara Berteotti, Matteo Cerri, Marco Luppi, Alessandro Silvani, Roberto Amici
      Pages 3-23
    3. Michael Thorpy
      Pages 71-83
  3. Drugs to Treat Insomnia

    1. Front Matter
      Pages 109-109
    2. Dimitri Markov, Karl Doghramji
      Pages 111-119
    3. Fabiana d’ Aniello, Benjamin Santos, Antonio Guglietta
      Pages 121-145
    4. Luc Staner
      Pages 147-157
    5. Alberto K. De la Herrán-Arita, Ana C. Equihua-Benítez, René Drucker-Colín
      Pages 191-207
  4. Drugs to Treat Excessive Daytime Sleepiness

    1. Front Matter
      Pages 209-209
    2. Karel Šonka, Peter Šóš, Marek Susta
      Pages 211-229
    3. Ahmed S. BaHammam, David Nelson Neubauer, Seithikurippu R. Pandi-Perumal
      Pages 231-248
    4. Oscar Arias-Carrión
      Pages 249-258
  5. Drugs to Treat Circadian Sleep Disorders

    1. Front Matter
      Pages 259-259
    2. David N. Neubauer, Ahmed S. BaHammam, Seithikurppu R. Pandi-Perumal
      Pages 261-269
  6. Conclusive Remarks

    1. Front Matter
      Pages 271-271

About this book


Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.


Drugs acting on the GABA receptor Excessive daytime sleepiness Hypnotics Insomnia Narcolepsy

Editors and affiliations

  • Antonio Guglietta
    • 1
  1. 1.Independent Pharmaceutical ConsultantBarcelonaSpain

Bibliographic information

Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods


“This book explores major breakthroughs in the drug treatment of sleep disorders. … The intended audience is scientists, clinicians, and drug developers. … With its specific aim of providing an extensive update on drug treatment for sleep disorders, this book is helpful contribution to sleep medicine.” (M. Isabel L. Crisostomo, Doody’s Book Reviews, July, 2015)